NASDAQ:IDXG
Interpace Diagnostics Group Stock News
$1.41
+0 (+0%)
At Close: May 03, 2024
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
11:55am, Tuesday, 11'th Feb 2020
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR® miRNA classi
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership
11:55am, Thursday, 30'th Jan 2020
Ron Rocca, CEO of Exagen, appointed to BoardJames Early, CFO announces retirement; Fred Knechtel, formerly CFO of GENEWIZ, appointed as CFOJeff Salzman, formerly of CareDX,.
Interpace Diagnostics Group (NASDAQ:IDXG) & ICU Medical (NASDAQ:ICUI) Critical Contrast
08:54am, Thursday, 16'th Jan 2020
Interpace Diagnostics Group (NASDAQ:IDXG) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their d
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
11:55am, Monday, 13'th Jan 2020
1315 Capital and Ampersand are two leading private equity firms investing in laboratory services. The new Series B Preferred Stock investment will be convertible into common stock at a conversion pri
Edited Transcript of IDXG earnings conference call or presentation 13-Nov-19 9:30pm GMT
12:33pm, Wednesday, 08'th Jan 2020
Q3 2019 Interpace Diagnostics Group Inc Earnings Call
Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary, Interpace Diagnostics has entered into a collabor
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
11:55am, Tuesday, 17'th Dec 2019
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT®
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
11:55am, Thursday, 05'th Dec 2019
Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer trans
Interpace Biosciences Launches New Corporate Website
11:55am, Monday, 02'nd Dec 2019
Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharma Solutions businesses of Interpace are repre
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew.
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019
11:55am, Tuesday, 12'th Nov 2019
Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to dis
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
11:55am, Monday, 04'th Nov 2019
Interpace Group (IDXG) Interpace Diagnostics announced today the publication of two peer-reviewed journal articles and one textbook chapter supporting the clinical utility of ThyGeNEXT® when used alo
Interpace to Present Data at the ATA Annual Meeting
10:55am, Tuesday, 29'th Oct 2019
Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual Meeting of the American Thyroid Association (ATA),
